Commercialization Plan GCC Cancer VaccineGCC CAR-T Viral Gene has completed the phase I clinical trial and is in the process of applying for an FDA approval to conduct a phase II clinical trial Expected to be designated as an orphan drug and breakthrough therapy Early entry into the market is anticipated upon completion of the phase II clinical trial Viral Gene possesses the right to commercialize the GCC Cancer Vaccine worldwide Phase IIa clinical trial expected to begin in 2019 with planned completion in 2021 During this stage, Viral Gene is planning to execute license agreements with global pharmaceutical companies for commercialization and sales Expect to generate earnings after 2021 through these agreements Phase IIb clinical trial completion expected by 2023 with anticipated market release in 2024-2025 Expect to generate continuous earnings from running royalties through sales beginning in 2024-2025 Liminatus has completed the preclinical trial stage and is in the process of applying for an FDA approval to conduct phase I clinical trial Expected to be designated as an orphan drug and breakthrough therapy Early entry into the market is anticipated upon completion of the phase II clinical trial Liminatus possesses the right to commercialize the GCC CAR-T worldwide Phase I clinical trial expected to begin in 2020 with planned completion in 2022 During this stage, Liminatus is planning to execute license agreements with global pharmaceutical companies for commercialization and sales Expect to generate earnings after 2022 through these agreements Phase II clinical trial completion expected by 2025 with anticipated market release in 2026 Expect to generate continuous earnings from running royalties through sales beginning in 2026
